BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Elotuzumab
Drug: Dexamethasone
Drug: Lenalidomide
Drug: Bortezomib
Drug: Pomalidomide
Drug: Nivolumab

First Posted Date: 2016-03-25

Last Posted Date: 2025-06-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 67

Registration Number: NCT02719613

Locations: 🇺🇸
Local Institution - 0009, Atlanta, Georgia, United States
🇺🇸
Local Institution - 0002, Boston, Massachusetts, United States
🇯🇵
Local Institution - 0048, Koto-ku, Tokyo, Japan

and more 38 locations

Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma

Completed

Conditions: Melanoma

First Posted Date: 2016-03-23

Last Posted Date: 2022-02-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 556

Registration Number: NCT02717364

Locations: 🇯🇵
Local Institution, Tokyo, Japan

Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France

Completed

Conditions: Anticoagulation

First Posted Date: 2016-03-22

Last Posted Date: 2017-04-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 2081

Registration Number: NCT02714855

Locations: 🇫🇷
Local Institution, Fontaine Les Dijon, France

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Phase 3

Completed

Conditions: Melanoma

Interventions: Biological: Nivolumab 1 mg/kg IV
Biological: Nivolumab 3 mg/kg IV
Biological: Nivolumab 6 mg/kg IV
Biological: Ipilimumab 1 mg/kg IV
Biological: Ipilimumab 3 mg/kg IV

First Posted Date: 2016-03-21

Last Posted Date: 2022-06-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 387

Registration Number: NCT02714218

Locations: 🇺🇸
Allina Health, Fridley, Minnesota, United States
🇺🇸
Washington University School Of Medicine, Saint Louis, Missouri, United States
🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

and more 41 locations

A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Phase 3

Completed

Conditions: Lung Cancer

Interventions: Biological: Nivolumab

First Posted Date: 2016-03-21

Last Posted Date: 2023-02-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 363

Registration Number: NCT02713867

Locations: 🇺🇸
Local Institution - 0089, Hollywood, Florida, United States
🇺🇸
Hematology And Oncology Associates, Canton, Ohio, United States
🇺🇸
Local Institution - 0116, Tupelo, Mississippi, United States

and more 113 locations

Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: BMS-986195
Other: Placebo

First Posted Date: 2016-03-11

Last Posted Date: 2019-01-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 439

Registration Number: NCT02705989

Locations: 🇦🇺
Local Institution, Melbourne, Victoria, Australia

Head and Neck Cancer Treatment Patterns and Outcomes Research Study in France, Germany, and Canada

Completed

Conditions: Head and Neck Cancer

First Posted Date: 2016-03-11

Last Posted Date: 2017-04-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 591

Registration Number: NCT02705833

A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection

Phase 3

Completed

Conditions: Hepatitis C

Interventions: Drug: DCV
Drug: SOF
Drug: RBV

First Posted Date: 2016-02-04

Last Posted Date: 2018-05-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 106

Registration Number: NCT02673489

Locations: 🇺🇸
Northeast Clinical Research Center, Bethlehem, Pennsylvania, United States
🇺🇸
Bon Secours St. Mary's Hospital of Richmond, Inc, Richmond, Virginia, United States
🇺🇸
University Gastroenterology, Providence, Rhode Island, United States

and more 10 locations

Evaluation of Hospital Readmissions Among Hospitalized Non-valvular Atrial Fibrillation (NVAF) Patients in the US

Completed

Conditions: Nonvalvular Atrial Fibrillation

First Posted Date: 2016-02-04

Last Posted Date: 2016-04-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 30000

Registration Number: NCT02674594

Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"

Phase 2

Completed

Conditions: Thrombosis

Interventions: Drug: Aspirin
Drug: BMS-986141
Other: Placebo

First Posted Date: 2016-02-02

Last Posted Date: 2018-12-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 16

Registration Number: NCT02671461

Locations: 🇺🇸
York Hospital, York, Pennsylvania, United States
🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 20 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy